LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. To learn more, please visit www.VIZZ.com.

Our Leadership

Latest Financial Results

FY 2025

Fiscal Year Ended Dec 31, 2025

Earnings Release PDF

Earnings Webcast

10-K PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Latest News

May 4, 2026 • 8:00 AM EDT

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

View Press Release View All News

Upcoming Event

May 11, 2026 4:30 pm EDT

Lenz Therapeutics First Quarter 2026 Financial Results and Business Update

View Event Add to Calendar View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449